Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV‑2 Spike Glycoprotein

Mert Golcuk, Aysima Hacisuleyman, Burak Erman, Ahmet Yildiz, Mert Gur*

*Bu çalışma için yazışmadan sorumlu yazar

Araştırma sonucu: ???type-name???Makalebilirkişi

9 Atıf (Scopus)

Özet

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters human cells upon binding of its spike (S) glycoproteins to ACE2 receptors. Several nanobodies neutralize SARS-CoV-2 infection by binding to the receptor-binding domain (RBD) of the S protein, but how their binding antagonizes S-ACE2 interactions is not well understood. Here, we identified interactions between the RBD and nanobodies H11-H4, H11-D4, and Ty1 by performing all-atom molecular dynamics simulations. H11-H4 and H11-D4 can bind to RBD without overlapping with ACE2. H11-H4, and to a lesser extent H11-D4, binding dislocates ACE2 from its binding site due to electrostatic repulsion. In comparison, Ty1 overlaps with ACE2 on RBD and has a similar binding strength to ACE2. Mutations in the Alpha variant of SARS-CoV-2 had a minor effect in RBD binding strengths of ACE2 and nanobodies, but reduced the ability of H11-H4 and H11-D4 to dislocate ACE2 from RBD. In comparison, the Beta variant weakened the RBD binding strengths of H11-H4 and H11-D4, which were less effective to dislocate ACE2 binding. Unexpectedly, mutations in Beta strengthened Ty1 binding to RBD, suggesting that this nanobody may be more effective to neutralize the Beta variant of SARS-CoV-2.

Orijinal dilİngilizce
Sayfa (başlangıç-bitiş)5152-5160
Sayfa sayısı9
DergiJournal of Chemical Information and Modeling
Hacim61
Basın numarası10
DOI'lar
Yayın durumuYayınlandı - 28 Eyl 2021

Bibliyografik not

Publisher Copyright:
© 2021 American Chemical Society.

Finansman

This work used resources services and support provided via the COVID-19 HPC Consortium ( https://covid19-hpc-consortium.org/ ) and the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant number ACI-1548562. A.Y. acknowledges to support of the National Institute of Health (1R35GM136414). This work is supported by COVID-19 HPC Consortium (Grant number: TG-BIO200053) and the National Institute of Health (R35 GM136414; A.Y.).

FinansörlerFinansör numarası
National Science FoundationACI-1548562
National Institutes of Health1R35GM136414

    Parmak izi

    Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV‑2 Spike Glycoprotein' araştırma başlıklarına git. Birlikte benzersiz bir parmak izi oluştururlar.

    Alıntı Yap